Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS‐CoV‐2 infection in vitro

• DOI: 10.1111/bph.15418
• Publication Date: 2021-04-07T04:00:31Z
• Authors: Sebastian Schloer; Linda Brunotte; Angeles Mecate‐Za...; Shuyu Zheng; Jing Tang; Stephan Ludwig; Ursula Rescher
• Keywords: PHARMACOKINETICS; 2; SARS‐ remdesivir; Pharmacy; Antiviral Agents; combination therapy; 03 medical and health sciences; Fluoxetine; CoV‐ Humans; PHARMACOLOGY; 0303 health sciences; Alanine; drug repurposing; SARS-CoV-2; fluoxetine; Hepatitis C, Chronic; CONCISE GUIDE; Research Papers; Adenosine Monophosphate; itraconazole; COVID-19 Drug Treatment; 3. Good health; Pharmaceutical Preparations; VIRUS; Itraconazole; INHIBITORS

Background and PurposeThe SARS‐COV‐2 pandemic and the global spread of coronavirus disease 2019 (COVID‐19) urgently call for efficient and safe antiviral treatment strategies. A straightforward approach to speed up drug development at lower costs is drug repurposing. Here, we investigated the therapeutic potential of targeting the interface of SARS CoV‐2 with the host via repurposing of clinically licensed drugs and evaluated their use in combinatory treatments with virus‐ and host‐directed drugs in vitro.Experimental ApproachWe tested the antiviral potential of the antifungal itraconazole and the antidepressant fluoxetine on the production of infectious SARS‐CoV‐2 particles in the polarized Calu‐3 cell culture model and evaluated the added benefit of a combinatory use of these host‐directed drugs with the direct acting antiviral remdesivir, an inhibitor of viral RNA polymerase.Key ResultsDrug treatments were well‐tolerated and potently impaired viral replication. Importantly, both itraconazole–remdesivir and fluoxetine–remdesivir combinations inhibited the production of infectious SARS‐CoV‐2 particles > 90% and displayed synergistic effects, as determined in commonly used reference models for drug interaction.Conclusion and ImplicationsItraconazole–remdesivir and fluoxetine–remdesivir combinations are promising starting points for therapeutic options to control SARS‐CoV‐2 infection and severe progression of COVID‐19.